compound 21

01/01/2019 - "Dose-response, therapeutic time-window and tPA-combinatorial efficacy of compound 21: A randomized, blinded preclinical trial in a rat model of thromboembolic stroke."
01/01/2017 - "Our objectives were to assess the long-term protective effects of post-stroke C21 treatments in a clinically-relevant model of stroke in aged rats and to characterize the cellular localization of AT2Rs in the mouse brain of transgenic reporter mice following stroke. "
01/01/2020 - "Delayed administration of C21 3 days post-stroke reduced mortality and improved sensorimotor and cognitive deficits. "
01/01/2015 - "This study aimed to investigate the effect of C21 administration on early and late stroke outcomes, and the molecular mediators involved. "
07/01/2022 - "Our findings demonstrate that C21 treatment preserves cognitive function, maintains cerebral blood flow, and reduces Aβ accumulation and toxic tau phosphorylation in AD animals post-stroke."

01/01/2015 - "After 3 h of MCAO, C21 treatment reduced infarct size and improved behavioural outcome at 24 h without affecting blood pressure. "
01/01/2016 - "This effect of C21 compound was mainly observed in neurons of the peri-infarct area. "
01/01/2016 - "Furthermore, the number of apoptotic neurons was significantly decreased in the peri-infarct cortex in mice treated with C21 compared to controls. "
01/01/2016 - "C21 treatment had no impact on infarct size, but significantly attenuated neurological deficits. "
03/01/2010 - "Moreover, it provides an overview of the first results obtained by direct AT(2) receptor stimulation with Compound 21, comprising effects on alkaline secretion, neurite outgrowth, blood pressure and post-infarct cardiac function."

01/01/2019 - "NEW & NOTEWORTHY The present study shows the neuroprotective impact of C21 on ischemic stroke in female rats and how the protective effects of C21 can be influenced by the hormonal status of female rodents."
01/01/2015 - "Compound 21 is pro-angiogenic in the brain and results in sustained recovery after ischemic stroke."
06/01/2014 - "Here, we hypothesize that C21 may exert beneficial effects against cerebral damage and neurological deficits produced by ischemic stroke. "
01/01/2018 - "Protective effects of the angiotensin II AT2 receptor agonist compound 21 in ischemic stroke: a nose-to-brain delivery approach."
01/01/2017 - "Intraperitoneal injections of C21 (0.03mg/kg) after ischemic stroke induced by transient monofilament middle cerebral artery occlusion resulted in protective effects that were sustained for up to at least 3-weeks post-stroke. "

05/01/2015 - "AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy."
11/15/2017 - "The review analyses the new therapeutic tool, C21, its mechanisms of action for renoprotection in diabetic nephropathy, and its future perspectives and thereby provides an insight into the potential application of C21 as a novel therapeutic tool in the eradication of diabetic nephropathy."
11/15/2017 - "A pool of evidences suggest that C21, either alone or in combination with angiotensin receptor blockers could be extremely beneficial in the treatment of diabetic nephropathy, a chronic inflammatory condition sharing its pathogenesis with aforementioned diseases. "
05/01/2015 - "This study aimed to elucidate the reno-protective role of the novel selective angiotensin II type 2 receptor agonist, Compound 21, in an experimental model of type 1 diabetic nephropathy. "
11/15/2017 - "AT2 receptor agonist Compound 21: A silver lining for diabetic nephropathy."

11/01/2023 - "Combined use of C21 and LOS was most beneficial for DOX induced heart failure."
12/23/2021 - "Compound 21 displayed excellent pharmacokinetic profiles in rat, monkey, and dog models and robust pharmacodynamic efficacy in the rodent heart failure model. "
12/23/2021 - "Identification of a Hydroxypyrimidinone Compound (21) as a Potent APJ Receptor Agonist for the Potential Treatment of Heart Failure."
10/01/2014 - "In this study, we hypothesized that C21 exerts a similar effect in rats with coronary ligation-induced heart failure (HF). "
01/01/2021 - "According to the results of echocardiographic and biochemical evaluations, C21, and Valsartan showed protective effects against heart failure. "